



(51) International Patent Classification:

C07C 311/48 (2006.01) **C07D 307/52** (2006.01)
C07D 231/12 (2006.01) **C07D 333/36** (2006.01)
C07D 213/36 (2006.01) **C07D 413/12** (2006.01)
C07D 243/08 (2006.01) **A61K 31/18** (2006.01)
C07D 261/08 (2006.01) **A61P 29/00** (2006.01)
C07D 307/14 (2006.01)

(21) International Application Number:

PCT/EP2009/060061

(22) International Filing Date:

3 August 2009 (03.08.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

08161765.6 4 August 2008 (04.08.2008) EP
 61/161,627 19 March 2009 (19.03.2009) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAETTIG, Urs** [CH/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **D'SOUZA, Anne-Marie** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **HUNT, Peter** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **PRESS, Neil John** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **WATSON, Simon James** [GB/GB]; Novartis Horsham

Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB).

(74) Agent: **VOEGELI-LANGE, Regina**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: ORGANIC COMPOUNDS



(57) Abstract: The present invention relates to compounds of Formula (I) wherein X, R¹, R², R³, R⁴ and R⁵ are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.